Cause of Seizures in a Patient with Previous PTB Treatment
The most likely cause of seizures in a patient who has recently completed anti-tuberculosis therapy is drug-induced neurotoxicity, primarily from isoniazid (INH), though cycloserine and fluoroquinolones (if used for drug-resistant TB) are also important culprits.
Primary Drug Culprits
Isoniazid (First-Line Agent)
Isoniazid is the most common cause of seizures among first-line anti-TB drugs 1, 2. The mechanism involves:
- GABAergic disruption through pyridoxine (vitamin B6) depletion, which reduces GABA synthesis and lowers the seizure threshold 3
- Seizures can occur even at therapeutic doses (not just overdose), as documented in multiple case reports 4, 5
- Risk is dose-dependent but unpredictable in individual patients
Key risk factors for INH-induced seizures:
- Diabetes mellitus
- Alcohol use disorder (especially with alcohol-related hepatitis) 6
- HIV infection
- Chronic renal failure
- Malnutrition
- Pre-existing seizure disorders 6
Cycloserine (Second-Line Agent)
If the patient received treatment for drug-resistant TB, cycloserine is a major seizure risk 6:
- Seizures reported in up to 16% of patients receiving 500 mg twice daily but only 3% at 500 mg once daily 6
- Central nervous system effects range from headache and restlessness to psychosis and seizures
- Particularly dangerous in patients with alcohol-related hepatitis (increased seizure risk) 6
Fluoroquinolones (Second-Line Agent)
Levofloxacin and other fluoroquinolones can induce seizures, especially in patients with renal impairment 7:
- Neurotoxicity manifests as focal or generalized seizures
- Risk dramatically increased in chronic kidney disease patients
- Seizures typically occur within 48-72 hours of drug initiation 7
Differential Diagnosis Algorithm
When evaluating seizures post-TB treatment, systematically exclude:
CNS tuberculosis complications:
Metabolic derangements:
- Drug-induced hepatotoxicity causing hepatic encephalopathy
- Hyponatremia (SIADH from TB or drugs)
- Hypoglycemia
- Uremia (especially if on aminoglycosides or fluoroquinolones)
Structural CNS lesions:
- Obtain brain imaging (MRI preferred) to exclude tuberculomas, abscesses, or other mass lesions 8
Drug interactions:
- Rifampicin induces hepatic metabolism and can reduce levels of anticonvulsants (phenytoin, carbamazepine), potentially unmasking underlying seizure disorders 6
Clinical Approach
Immediate assessment should focus on:
- Timing: Seizures during active treatment suggest drug toxicity; seizures after treatment completion suggest CNS tuberculosis complications
- Renal function: Critical for fluoroquinolone and cycloserine toxicity 7, 6
- Hepatic function: Hepatotoxicity increases seizure risk with multiple TB drugs 6
- Alcohol history: Dramatically increases risk with INH and cycloserine 6
- Drug regimen specifics: Which drugs were used? Standard vs. drug-resistant regimen?
Diagnostic workup:
- Brain MRI with contrast (to exclude tuberculomas or other structural lesions)
- Comprehensive metabolic panel including liver and renal function
- Serum drug levels if cycloserine was used (target peak 20-35 mg/mL) 6
- EEG if seizure type unclear
Management Principles
If drug-induced seizures are suspected:
Administer pyridoxine 100-200 mg daily if INH-related (both therapeutic and preventive) 6
Initiate anticonvulsant therapy as needed for seizure control
Modify TB regimen:
- Replace offending drug with alternative agent
- Critical caveat: In tuberculous meningitis, stopping anti-TB drugs is an independent risk factor for death 9, so substitution rather than discontinuation is essential
Prevention Strategies
Pyridoxine prophylaxis (10 mg daily) should be given to high-risk patients 1:
- Diabetics
- Alcoholics
- HIV-positive patients
- Chronic renal failure
- Malnourished patients
For cycloserine use:
- Monthly neuropsychiatric assessment mandatory 6
- Use lowest effective dose (prefer 500 mg once daily over 500 mg twice daily)
- Measure serum concentrations to optimize dosing 6
For fluoroquinolones in renal disease:
- Mandatory dose adjustment based on creatinine clearance 7
- Close neurological monitoring in first 72 hours
Common Pitfalls
- Assuming all seizures are drug-related: Always image the brain to exclude tuberculomas, which can present identically 8
- Stopping all TB drugs: This increases mortality risk, especially in CNS TB; substitute rather than discontinue 9
- Failing to provide pyridoxine prophylaxis: Simple, inexpensive prevention for high-risk patients 1
- Inadequate dose adjustment in renal failure: Fluoroquinolones and cycloserine require careful dosing 6, 7